STLNStarling Oncology Inc. Common Stock
6.465USD-2.93%Mkt Cap: 658.89M $P/E: —3d ago
Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company of…
Industry Peers
Medical Care Facilities$95.21BUSDP/E 14.4
$28.53BUSDP/E 16.8
$22.61BUSDP/E 10.9
$11.72BUSDP/E 12.1
$12.47BUSDP/E 12.2
$11.87BUSDP/E 20.1
$11.16BUSDP/E 14.7
$10.46BUSDP/E 28.1
$10.45BUSDP/E 7.2
$7.07BUSDP/E 27.2
$7.00BUSDP/E 25.9
$4.76BUSDP/E 95.9
$4.46BUSDP/E 22.6
$3.50BUSDP/E 39.0
$3.66BUSDP/E 26.2
$3.55BUSDP/E 18.0
$2.87BUSDP/E 10.3
$2.82BUSD
$2.45BUSD
$2.59BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
 Oncology Institute Q2 Earnings Call Highlights Oncology Institute (NASDAQ:TOI) reported second-quarter revenue growth, positive adjusted EBITDA and an expanded pipeline of value-based oncology contracts as the company announced it has rebranded as Starling Oncology. Chief Executive Officer Dan Virnich said the new name reflects the company’s ev | ||
 The Oncology Institute, Inc. (STLN) Reports Q2 Loss, Tops Revenue Estimates STARLING ONCOLO (STLN) delivered earnings and revenue surprises of -14.29% and +5.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||